A real-world retrospective study (44) encompassing 53 patients with ALK fusion gene-positive advanced NSCLC categorized into two age groups (<65 and ≥65 years) and treated with crizotinib, ceritinib, and alectinib respectively, found that age did not significantly impact PFS and OS in either group. Here, ALK is linked to non-small cell lung carcinoma.